Blueprint Medicines
134 articles with Blueprint Medicines
-
Blueprint Medicines Corporation and privately held CStone Pharmaceuticals have entered into a partnership to develop and commercialize avapritinib, BLU-554 and BLU-667 in mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies.
-
Blueprint Medicines to Present at Upcoming Investor Conferences in June 2018
5/31/2018
Blueprint Medicines Corporation announced its participation in several upcoming investor conferences.
-
Blueprint Medicines Reports First Quarter 2018 Financial Results
5/2/2018
Blueprint Medicines Corporation reported financial results and provided a business update for the quarter ended March 31, 2018.
-
Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018
4/25/2018
Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 2, 2018 to report its first quarter 2018 financial results and provide a corporate update.
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results
2/21/2018
Blueprint Medicines Corporation, a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2017.
-
Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018
2/16/2018
The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
-
Blueprint Medicines, Corp. Announces Pricing of Public Offering of Shares of Common Stock
12/13/2017
Blueprint Medicines today announced the pricing of an underwritten public offering of 3,703,704 shares of its common stock at a public offering price of $81.00 per share, before underwriting discounts and commissions.
-
Blueprint Medicines Corp. Announces Proposed Public Offering of Shares of Common Stock
12/12/2017
Blueprint Medicines today announced that it has commenced an underwritten public offering of $275,000,000 in shares of its common stock.
-
ASH Burns Bright With Excitement
12/12/2017
A look at some of the exciting data clinicians and investors got to feast on from ASH. -
Blueprint Medicines Announces New Data From Ongoing Phase I Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
12/11/2017
The new data from the dose escalation portion of the Phase I trial showed strong clinical activity regardless of advanced SM subtype, prior treatment with midostaurin or the presence of additional mutations.
-
Blueprint Medicines Announces New Data From Ongoing Phase I Clinical Trial of BLU-285 in Patients With Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity Across Spectrum of KIT and Pdgfrα Genotypes
11/10/2017
The data confirm and build upon data previously presented for BLU-285 in patients with advanced GIST, demonstrating robust clinical activity and a favorable safety profile.
-
Blueprint Announces Appointment Of Christopher Murray, Ph.D. As Senior Vice President, Technical Operations
10/11/2017
-
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma
7/28/2017
-
Booming Blueprint to Expand Into Former GlaxoSmithKline Site
5/5/2017